AR104918A1 - Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo - Google Patents

Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo

Info

Publication number
AR104918A1
AR104918A1 ARP160101679A ARP160101679A AR104918A1 AR 104918 A1 AR104918 A1 AR 104918A1 AR P160101679 A ARP160101679 A AR P160101679A AR P160101679 A ARP160101679 A AR P160101679A AR 104918 A1 AR104918 A1 AR 104918A1
Authority
AR
Argentina
Prior art keywords
azetidin
ethylsulfonyl
acetonitrile
formula
pyrazol
Prior art date
Application number
ARP160101679A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56204068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR104918(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR104918A1 publication Critical patent/AR104918A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente se refiere a procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]azetidin-3-il}acetonitrilo de fórmula [1]. Reivindicación 1: Un proceso para la preparación de {1-(etilsulfonil)-3-[4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]azetidin-3-il}acetonitrilo de fórmula [1], caracterizado porque comprende las etapas de: i) acoplar clorhidrato de azetidin-3-ol (2) con cloruro de etansulfonilo para dar 1-etilsulfonilazetidin-3-ol (3); ii) oxidación aeróbica de 1-etilsulfonilazetidin-3-ol (3) a 1-(etilsulfonil)azetidin-3-ona (4) en la presencia de un reactivo de nitroxilo, un agente oxidante, y un ácido bajo una atmósfera de oxígeno; u oxidación de 1-etilsulfonilazetidin-3-ol (3) a 1-(etilsulfonil)azetidin-3-ona (4) con TCCA y un reactivo catalítico de oxamonio; iii) reacción de 1-(etilsulfonil)azetidin-3-ona (4) con un reactivo de fosfonato en la presencia de una base para preparar el compuesto (1); iv) opcionalmente cristalizar [1-(etilsulfonil)azetidin-3-iliden]acetonitrilo (1); v) opcionalmente proteger 4-(4,4,5,5-tetrametil-1,3,2-dioxaborolan-2-il)-1H-pirazol (5) con un grupo protector de nitrógeno; vi) acoplar [1-(etilsulfonil)azetidin-3-iliden]acetonitrilo (1) y 4-(4,4,5,5-tetrametil-1,3,2-dioxaborolan-2-il)-1H-pirazol (5) en la presencia de una base no nucleofílica para dar {1-(etilsulfonil)-3-[4-(4,4,5,5-tetrametil-1,3,2-dioxaborolan-2-il)-1H-pirazol-1-il]azetidin-3-il}acetonitrilo de fórmula [2]; vii) opcionalmente cristalizar {1-(etilsulfonil)-3-[4-(4,4,5,5-tetrametil-1,3,2-dioxaborolan-2-il)-1H-pirazol-1-il]azetidin-3-il}acetonitrilo de fórmula [2]; viii) opcionalmente proteger 4-cloro-7H-pirrolo[2,3-d]pirimidina (7a) con un grupo protector de nitrógeno; ix) acoplar {1-(etilsulfonil)-3-[4-(4,4,5,5-tetrametil-1,3,2-dioxaborolan-2-il)-1H-pirazol-1-il]azetidin-3-il}acetonitrilo de fórmula [2] con 4-cloro-7H-pirrolo[2,3-d]pirimidina (7a) o 4-cloropirrolo[2,3d]pirimidina-7-carboxilato de terc-butilo (7b) usando un catalizador de Pd(III) en la presencia de una base para proporcionar {1-(etilsulfonil)-3-[4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]azetidin-3-il}acetonitrilo de fórmula [1] o 4-{1-[3-(cianometil)-1-(etilsulfonil)azetidin-3-il]-1H-pirazol-4-il}-7H-pirrolo[2,3-d]pirimidina-7-carboxilato de terc-butilo de fórmula [3]; x) opcionalmente desproteger 4-{1-[3-(cianometil)-1-(etilsulfonil)azetidin-3-il]-1H-pirazol-4-il}-7H-pirrolo[2,3-d]pirimidina-7-carboxilato de terc-butilo de fórmula [3] a {1-(etilsulfonil)-3-[4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]azetidin-3-il}acetonitrilo de fórmula [1]; y xi) opcionalmente cristalizar {1-(etilsulfonil)-3-[4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]azetidin-3-il}acetonitrilo de fórmula [1]. Reivindicación 18: El compuesto, caracterizado porque es 2-[1-etilsulfonil-3-[4-(4,4,5,5-tetrametil-1,3,2-dioxaborolan-2-il)pirazol-1-il]azetidin-3-il]acetonitrilo de fórmula [2]. Reivindicación 19: El uso del compuesto, 2-[1-etilsulfonil-3-[4-(4,4,5,5-tetrametil-1,3,2-dioxaborolan-2-il)pirazol-1-il]azetidin-3-il]acetonitrilo de fórmula [2] para preparar {1-(etilsulfonil)-3-[4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]azetidin-3-il} acetonitrilo de fórmula [1].
ARP160101679A 2015-06-19 2016-06-06 Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo AR104918A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562182040P 2015-06-19 2015-06-19

Publications (1)

Publication Number Publication Date
AR104918A1 true AR104918A1 (es) 2017-08-23

Family

ID=56204068

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101679A AR104918A1 (es) 2015-06-19 2016-06-06 Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo

Country Status (26)

Country Link
US (2) US20180134713A1 (es)
EP (1) EP3310781A1 (es)
JP (1) JP2018519280A (es)
KR (1) KR20180008637A (es)
CN (1) CN107660206A (es)
AR (1) AR104918A1 (es)
AU (1) AU2016280815A1 (es)
BR (1) BR112017024613A2 (es)
CA (1) CA2984627A1 (es)
CL (1) CL2017003112A1 (es)
CO (1) CO2017013226A2 (es)
CR (1) CR20170533A (es)
DO (1) DOP2017000300A (es)
EA (1) EA201792308A1 (es)
EC (1) ECSP17083426A (es)
HK (1) HK1248699A1 (es)
IL (1) IL255386A0 (es)
MA (1) MA45901A (es)
MX (1) MX2017015837A (es)
NZ (1) NZ736999A (es)
PE (1) PE20180504A1 (es)
PH (1) PH12017502360A1 (es)
SV (1) SV2017005586A (es)
TN (1) TN2017000530A1 (es)
TW (1) TWI622591B (es)
WO (1) WO2016205487A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108341818A (zh) * 2017-01-21 2018-07-31 南京华威医药科技开发有限公司 巴瑞克替尼及其磷酸盐的新晶型及其制备方法
US11524961B2 (en) 2017-01-23 2022-12-13 Shanghai Longwood Biopharmaceuticals Co., Ltd. JAK kinase inhibitor and preparation method and use thereof
CN106946917B (zh) * 2017-03-20 2019-06-11 杭州科巢生物科技有限公司 一种jak抑制剂巴瑞替尼及其中间体的新合成方法
CN107739328B (zh) * 2017-11-22 2020-03-20 海化生命(厦门)科技有限公司 用于合成巴瑞替尼的关键中间体1的制备方法
CN108129482A (zh) * 2017-12-13 2018-06-08 江苏中邦制药有限公司 一种巴瑞替尼的制备方法
US10766900B2 (en) 2017-12-29 2020-09-08 Formosa Laboratories, Inc. Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof
WO2020072870A1 (en) 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Co-crystal forms of baricitinib
TW202033198A (zh) 2018-10-17 2020-09-16 美商美國禮來大藥廠 以巴瑞克替尼(baricitinib)治療原發性膽汁性膽管炎及原發性硬化性膽管炎
CN114466681A (zh) 2019-04-24 2022-05-10 礼蓝美国公司 7h-吡咯并[2,3-d]嘧啶jak抑制剂
AU2022319128A1 (en) 2021-07-30 2024-01-18 Eli Lilly And Company Treatment of hand eczema with baricitinib

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821374A (en) * 1995-11-21 1998-10-13 Hoffmann-La Roche Inc. Process for the oxidation of alcohols
SI2288610T1 (sl) * 2008-03-11 2016-11-30 Incyte Holdings Corporation Derivati azetidina in ciklobutana kot inhibitorji jak
KR20130094710A (ko) * 2010-04-14 2013-08-26 어레이 바이오파마 인크. Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘
CN102557901B (zh) * 2010-12-15 2014-06-11 上海医药工业研究院 6-氯己醛的制备方法
EA030705B1 (ru) * 2013-03-06 2018-09-28 Инсайт Холдингс Корпорейшн Способы и промежуточные соединения при получении ингибитора jak
CN105541891B (zh) * 2016-02-04 2017-11-28 东南大学 巴瑞替尼的中间体及其制备方法及由该中间体制备巴瑞替尼的方法

Also Published As

Publication number Publication date
US20180134713A1 (en) 2018-05-17
MA45901A (fr) 2019-06-19
TWI622591B (zh) 2018-05-01
WO2016205487A1 (en) 2016-12-22
BR112017024613A2 (pt) 2018-07-31
CA2984627A1 (en) 2016-12-22
SV2017005586A (es) 2018-04-24
EP3310781A1 (en) 2018-04-25
PH12017502360A1 (en) 2018-06-25
ECSP17083426A (es) 2018-02-28
US20190062337A1 (en) 2019-02-28
AU2016280815A1 (en) 2017-11-23
PE20180504A1 (es) 2018-03-09
CR20170533A (es) 2018-01-25
KR20180008637A (ko) 2018-01-24
TW201712015A (zh) 2017-04-01
MX2017015837A (es) 2018-04-10
JP2018519280A (ja) 2018-07-19
CN107660206A (zh) 2018-02-02
DOP2017000300A (es) 2018-01-31
IL255386A0 (en) 2017-12-31
NZ736999A (en) 2019-05-31
CL2017003112A1 (es) 2018-06-01
EA201792308A1 (ru) 2018-05-31
HK1248699A1 (zh) 2018-10-19
TN2017000530A1 (en) 2019-04-12
CO2017013226A2 (es) 2018-03-28

Similar Documents

Publication Publication Date Title
AR104918A1 (es) Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo
HRP20201887T1 (hr) LIJEČENJE B-STANIČNIH MALIGNITETA S KOMBINACIJOM INHIBITORA JAK i PI3K
PE20091493A1 (es) Inhibidores de quinasa de pirrolopirazina
HUS2000006I1 (hu) Szubsztituált pirazolo[1,5-a]pirimidin vegyületek mint TRK kináz inhibitorok
ES2611588T3 (es) Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
NZ596479A (en) N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CL2021000611A1 (es) Proceso para preparar n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida por acoplamiento entre un indazol y una pirimidina; ciclación para formar un azabenzimidazol y desprotección del grupo indazol con tfa puro (divisional de la solicitud no. 201803423)
JP2017518276A5 (es)
MX2018014116A (es) Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil )pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirroli din-1-carboxamida y sales del mismo.
RU2015106787A (ru) Замещенные пирролы, активные в качестве ингибиторов киназ
PE20091211A1 (es) Derivados de pirazolopirimidina como moduladores de pde9a
HRP20070534T3 (en) Phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
PE20051089A1 (es) Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
PE20110944A1 (es) DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINA COMO INHIBIDORES PDE1
PH12015502705B1 (en) Processes of making and crystalline forms of a mdm2 inhibitor
MX2017016772A (es) Metodo para producir un derivado de 7h-pirrolo[2,3-d]pirimidina e intermediario del mismo.
MX2020006293A (es) Derivados de 5-(2-2,5-difluorofenil)pirrolidin-1-il)-3-(1h-pirazol -1-il)pirazolo[1,5-a]pirimidina y compuestos relacionados como inhibidores de trk cinasa para el tratamiento de cancer.
MA37649B1 (fr) Procédé de fabrication de composés cyclopentylpyrimidines hydroxylées
EA200800920A1 (ru) Производные пиразоло[4,3-d]пиримидин-5-ила, применяемые в качестве ингибиторов фосфодиэстеразы 5 (pde5)
MY171538A (en) Process for making amino compounds
PE20150965A1 (es) Azaindolinas
EP2552917A4 (en) PROCESS FOR THE SYNTHESIS OF 6-BROMO-3- (1-METHYL-1H-PYRAZOL-4-YL) -5- (3 (R) -PIPERIDINYL) PYRAZOLO [1,5-A] PYRIMIDIN-7-AMIN
MY173661A (en) Processes for the preparation of azd5363 and novel intermediate used therein
NZ625965A (en) Kinase inhibitors useful as anti-inflammatory agents
NZ625611A (en) Combination treatment of cancer

Legal Events

Date Code Title Description
FB Suspension of granting procedure